ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Proteinuria"

  • 2018 American Transplant Congress

    Antiproteinuric Effect of Spironolactone in Renal Transplantation: Effectiveness and Clinical Outcomes

    M. Sousa, C. Do Valle, G. Rivelli, L. Camargo, R. Zollner, M. Mazzali.

    University of Campinas, Campinas, Sao Paulo, Brazil.

    Background: aldosterone is involved in development of fibrosis in kidney transplantation. Blockade of aldosterone receptor appears to be effective in treatment for chronic allograft dysfunction,…
  • 2017 American Transplant Congress

    Renal Function, Albuminuria, and the Risk of Death and Graft Loss After Kidney Transplantation.

    N. Lam,1 M. Tonelli,2 K. Lentine,3 B. Hemmelgarn,2 F. Ye,1 K. Wen,1 S. Klarenbach.1

    1University of Alberta, Edmonton, Canada; 2University of Calgary, Calgary, Canada; 3Saint Louis University, St. Louis

    In 2012, the KDIGO guidelines updated the classification system for chronic kidney disease to include albuminuria. Whether this classification system prognosticates adverse clinical outcomes among…
  • 2017 American Transplant Congress

    Renal Function Outcomes by HLA Mismatch in De Novo Kidney Transplant Recipients Receiving Everolimus PlusReduced-Dose Cyclosporine versus Mycophenolate Plus Standard-Dose Cyclosporine: 24-Month Subanalysis of A1202 Study.

    K. Yoshida,1 Y. Watarai,2 K. Nakagawa,3 O. Kamisawa.4

    1Kitasato University, Sagamihara, Japan; 2Nagoya Daini Red Cross Hospital, Nagoya, Japan; 3Ichikawa General Hospital, Tokyo Dental College, Ichikawa, Japan; 4Novartis Pharma K.K., Tokyo, Japan

    Purpose: High levels of human leukocyte antigen (HLA) mismatches are a key determinant of kidney allograft survival. Here, we present 24-month (M) subanalysis of the…
  • 2017 American Transplant Congress

    Determinants of Successful Use of Sirolimus in Renal Transplantation.

    M. Naik,1 W. Gwinner,2 W. Arns,3 E. Basic,10 K. Budde,1 F. Diekmann,4 M. Fischereder,5 J. Goßmann,6 K. Heller,7 N. Heyne,8 J.-S. Jürgensen,1 C. Morath,9 U. Riester.10

    1GSSG, Berlin, Germany; 2GSSG, Hannover, Germany; 3GSSG, Köln, Germany; 4GSSG, Barcelona, Spain; 5GSSG, München, Germany; 6GSSG, Frankfurt, Germany; 7GSSG, Erlangen, Germany; 8GSSG, Tübingen, Germany; 9GSSG, Heidelberg, Germany; 10GSSG - Pfizer, Berlin, Germany

    Sirolimus (SLR) is an established component in the immunosuppressive treatment after renal transplantation.The side effects of SLR differ from other immunosuppressants and may limit its…
  • 2017 American Transplant Congress

    Early Introduction of Oral Paricalcitol in Renal Transplant Recipients. An Open-Label Randomized Study.

    H. Pihlstrøm,1 F. Gatti,2 C. Hammarstrom,2 I. Eide,1 M. Kasprzycka,2 J. Wang,2 G. Haraldsen,2 M. Svensson,3 K. Midtvedt,1 A. Hartmann,1 G. Mjøen,1 D. Dahle,1 H. Holdaas.1

    1Department of Surgery, Inflammation Medicine and Transplantation, Oslo University Hospital Rikshospitalet, Oslo, Norway; 2Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 3Department of Nephrology, Akershus University Hospital, Oslo, Norway

    In stable renal transplant recipients with hyperparathyroidism, the vitamin D agonist paricalcitol reduces level of proteinuria. Animal studies indicate possible anti-fibrotic and anti-inflammatory effects. The…
  • 2017 American Transplant Congress

    Interruption of RAAS in Hypertensive Proteinuric Kidney Donors.

    O. Sanchez,1 L. Ferrara,1 D. Berglund,1 A. Matas,2 R. Foley,1 H. Ibrahim.1

    1Department of Internal Medicine, U of MN, Mpls, MN; 2Department of Surgery, U of MN, Minneapolis, MN

    The aim of this analysis was to assess the progression of eGFR between proteinuric hypertensive living kidney donors (HTN-LKDs) receiving ACE inhibitors (ACEinh) or angiotensin…
  • 2017 American Transplant Congress

    Podocyte-Specific Knockdown of SHROOM3 Causes Albuminuria and Foot-Process Effacement by Interaction with FYN.

    M. Menon, N. Philippe, C. Wei, W. Zhang, J. He, B. Murphy.

    Nephrology, Medicine, Icahn School of Medicine, New York, NY

    In the translational GoCAR study, we identified that a CKD-associated SHROOM3-SNP, and tubular SHROOM3 expression correlated with the development of renal fibrosis post-transplant. The SNP…
  • 2017 American Transplant Congress

    RAS Inhibition Attenuates Urine Angiotensin II-Regulated Proteins Associated with Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.

    Z. Mohammed-Ali,1 S. Reid,3 P. Yip,1 H. Cardinal,2 M.-J. Hébert,2 Y. Li,4 S. Kim,1,3,4 A. Konvalinka.1,3

    1University Health Network, Toronto, ON, Canada; 2Centre de Recherche du Centre Hospitalier de l'Université de Montréal - CRCHUM, Montréal, QC, Canada; 3Institute of Medical Science, University of Toronto, Toronto, ON, Canada; 4Institute of Health Policy, University of Toronto, Toronto, ON, Canada

    Angiotensin-II (AngII), the main effector of the renin-angiotensin system (RAS), can lead to interstitial fibrosis/ tubular atrophy (IFTA) in kidney transplant recipients, mainly through AT-1R…
  • 2017 American Transplant Congress

    Acthar in Recurrent Focal Segmental Glomerular Sclerosis After Kidney Transplantation.

    T. Alhamad,1 J. Dieck,2 V. Vujjini,2 B. Kanawati,1 D. Brennan,1 N. Alachkar.2

    1Washington University in St. Louis, St. Louis; 2Johns Hopkins University, Baltimore

    Treatment of Recurrent focal segmental glomerular sclerosis (FSGS) after kidney transplantation is challenging with unpredictable outcomes. Conventional therapeutic options include various combinations of plasmapheresis, steroids,…
  • 2017 American Transplant Congress

    Treatment of Post-Transplant Nephrotic Syndrome with Adrenocorticotropic (ACTH) Gel.

    A. Khalil,2 A. Karabala,1 A. Sharfuddin,2 M. Grafals.1

    1Medstar Georgetown Transplant Institute, Washington DC; 2Indiana University Health, Indianapolis

    Objectives: Post-kidney transplant proteinuria due to recurrent GN is considered to be a significant risk factor negatively affecting kidney transplant survival. In this case series…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences